La hija de Cervantes: un dramma romantico inedito di Aureliano Fernández-Guerra y Orbe. Edizione critica e studio

Aureliano Fernandez-Guerra is known especially among Quevedo’s scholars because he published the first complete edition of Quevedo’s works. Few people know his plays and, for this reason, they have never been studied. These plays were written during his youth, when Fernández-Guerra hadn’t decided anything about his career yet. Therefore, these plays were always very important for him and, for this reason, he continued to correct and to revise them. Among them, the unpublished drama La hija de Cervantes (1840) was considered the most important play. In this doctoral thesis I have tried to describe this Spanish author, especially focusing on theatre. In the first part I wrote about the life and the literary works, giving particularly importance to his plays that are La peña de los enamorados (1939), La hija de Cervantes (1840), Alonso Cano (1842) and La Ricahembra (1845), this last one written in collaboration with Manuel Tamayo y Baus, another important and famous playwright. In the second part I deepened the study of La hija de Cervantes because it is a particular interesting drama: Aureliano Fernández-Guerra chose to represent the author of the Quixote as a character of his drama, especially dramatizing the most mysterious moments of his life, such as the Gaspar de Ezpeleta’s murder, his relationship with his daughter Isabel de Saavedra and his supposed love for a woman, whose existence his unknown. Besides, this drama is interesting because it is partially autobiographic: I found several letters and articles where it is emphasized the similarities between Cervantes’ and Aureliano’s life: both feel misunderstood and not appreciated by other people and both had to renounce a big love. In the final part I presented the critical edition of La hija de Cervantes based on the last three manuscripts that are today at the Institut de Teatre in Barcelona. A wide philological note shows the transcription criterions.

Johann Schöffer, Buchdrucker zu Mainz

Die Arbeit beschriebt das Leben und Wirken Johann Schöffers, des Erben der Mainzer Druckerei Johannes Fusts und Peter Schöffer d.Ä. Im Mittelpunkt stehen die 315 heute noch nachweisbaren Drucke. Neben der bibliographischen Erfassung der Titel, die ergänzt werden durch Hinweise zur Illustration und zur Typographie, wird versucht anhand dieser die Entwicklung und die Veränderungen in der Werkstatt aufzuzeigen. Von Interesse ist dabei, dass sich die historischen Ereignisse und religiösen Strömungen teilweise parallel, teilweise zeitlich versetzt im Verlagsprogramm widerspiegeln.

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial

OBJECTIVE: Dual antiplatelet therapy with clopidogrel plus acetylsalicylic acid (ASA) is superior to ASA alone in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention. We sought to determine whether clopidogrel plus ASA conferred benefit on limb outcomes over ASA alone in patients undergoing below-knee bypass grafting. METHODS: Patients undergoing unilateral, below-knee bypass graft for atherosclerotic peripheral arterial disease (PAD) were enrolled 2 to 4 days after surgery and were randomly assigned to clopidogrel 75 mg/day plus ASA 75 to 100 mg/day or placebo plus ASA 75 to 100 mg/day for 6 to 24 months. The primary efficacy endpoint was a composite of index-graft occlusion or revascularization, above-ankle amputation of the affected limb, or death. The primary safety endpoint was severe bleeding (Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries [GUSTO] classification). RESULTS: In the overall population, the primary endpoint occurred in 149 of 425 patients in the clopidogrel group vs 151 of 426 patients in the placebo (plus ASA) group (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.78-1.23). In a prespecified subgroup analysis, the primary endpoint was significantly reduced by clopidogrel in prosthetic graft patients (HR, 0.65; 95% CI, 0.45-0.95; P = .025) but not in venous graft patients (HR, 1.25; 95% CI, 0.94-1.67, not significant [NS]). A significant statistical interaction between treatment effect and graft type was observed (P(interaction) = .008). Although total bleeds were more frequent with clopidogrel, there was no significant difference between the rates of severe bleeding in the clopidogrel and placebo (plus ASA) groups (2.1% vs 1.2%). CONCLUSION: The combination of clopidogrel plus ASA did not improve limb or systemic outcomes in the overall population of PAD patients requiring below-knee bypass grafting. Subgroup analysis suggests that clopidogrel plus ASA confers benefit in patients receiving prosthetic grafts without significantly increasing major bleeding risk.